Thakeham

3Daughters Announces Three New Appointments to Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Quotient, Thakeham, Alnylam Pharmaceuticals, CDMO, Birth, Labs, GSK plc, Pharmacy, University, Novartis, Dana–Farber Cancer Institute, IUD, University College London, Embryology, IND, MBA, Woman, Doctor of Philosophy, Intrauterine device, Therapy, Drug development, Allergan, Amersham plc, Takeda Oncology, Chief Justice of Hungary, Pharmacia, Birth control

Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.

Key Points: 
  • Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.
  • An IND for 3D-001 will be filed this year followed by a Phase 1 clinical trial.
  • Mary Beth Cicero, CEO of 3Daughters, expressed her enthusiasm about the new additions to the board: "We are incredibly excited to have the collective strengths of Michele, Sarah, and Vin on our Board of Directors.
  • With this first product, 3Daughters expects to disrupt the IUD market and establish a position as a major innovator in women's healthcare.

IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine

Retrieved on: 
Wednesday, January 24, 2024
Patient, Therapy, Research, CSO, Health, Failure, Partnership, Liquid biopsy, Transplant, Chair, IMU, IND, Duke University, Blood, Takeda, Inga, Disease, COVID-19, Drug development, Safety, Thakeham, Molten Ventures, Medicine, Immune system, Vaccine

London, UK, 24 January 2024 — IMU Biosciences (or “the Company”), a techbio company revolutionising immune powered precision medicine, today announces the close of a £11.5 million Series A financing round.

Key Points: 
  • London, UK, 24 January 2024 — IMU Biosciences (or “the Company”), a techbio company revolutionising immune powered precision medicine, today announces the close of a £11.5 million Series A financing round.
  • IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease.
  • “This systems-level approach to understanding immune function enables us to look at the bigger picture rather than just focusing on individual disease-associated parameters.
  • IMU Biosciences has further validated and fine-tuned its unique approach in partnership with leading pharmaceutical and biotech companies.

Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF)

Retrieved on: 
Monday, October 30, 2023
FDA, AstraZeneca, Health, Therapy, Biotechnology, Eisai, CG, CCD, Growth, LLP, ACCD, Investment, Simpson Thacher & Bartlett, Patient, Pharmaceutical industry, Thakeham, Pfizer

Abingworth Clinical Co-Development Co-Investment Fund (CCD-CIF) was significantly oversubscribed, exceeding its target of $300 million.

Key Points: 
  • Abingworth Clinical Co-Development Co-Investment Fund (CCD-CIF) was significantly oversubscribed, exceeding its target of $300 million.
  • Alongside the Abingworth Clinical Co-Development Fund 2 (ACCD 2), a fund of $583 million, Abingworth has raised over $930 million in new funds since 2021 to invest in the development of late-stage clinical programs from pharmaceutical and biotechnology companies in the US, UK, Europe, and Asia-Pacific, and create innovative therapeutics with potential to significantly improve human health.
  • Abingworth pioneered the clinical co-development (CCD) investment strategy in 2009, investing initially via its venture funds and then through its first dedicated fund, Abingworth Clinical Co-Development Fund (ACCD 1), which launched in 2016 raising $109 million.
  • Overall, across all strategies – venture, growth, and clinical co-development – Abingworth has invested in over 185 life sciences companies over the last 50 years.

Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Technology, Neurology, Health Technology, Artificial Intelligence, Biotechnology, Nexus, Cloud, Therapy, OrbiMed, Venture round, HER2, Sequoia Capital, Health care, Partner (business rank), MBA, Partner, Patient, 2007–08 Serie B, NVIDIA, Cancer, Conference on Semantics in Healthcare and Life Sciences, Series, Drug discovery, Physics, Freeflow, AI, Software, Pharmaceutical industry, Medical device, Iamb, Thakeham

Existing investors also participated, including Nexus Ventures, Catalio Capital Management, Coatue, FreeFlow, OrbiMed, and Sequoia Capital.

Key Points: 
  • Existing investors also participated, including Nexus Ventures, Catalio Capital Management, Coatue, FreeFlow, OrbiMed, and Sequoia Capital.
  • As part of the Series B, Iambic is delighted to welcome two new board members, Evan Rachlin, M.D., from Ascenta Capital and Kurt von Emster from Abingworth.
  • Further, Iambic has extended its leadership position in the AI community, creating methods such as NeuralPLexer and OrbNet to drive its discovery platform.
  • It plans to leverage NVIDIA technology such as the NVIDIA DGX Cloud AI supercomputing platform and the NVIDIA BioNeMo cloud service to accelerate discovery.

Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

Retrieved on: 
Tuesday, June 20, 2023
Laboratory, Drug development, Professional Football Compensation Committee, University, Bureau of Oceans and International Environmental and Scientific Affairs, CSU, Horizon Therapeutics, Abbott Laboratories, Senior advisor, Medication, Champaign–Urbana metropolitan area, Technical Guidelines Development Committee, Harvard Medical School, Massachusetts Eye and Ear, Partner, AbbVie, Risk, Syndrome, Thakeham, Ophthalmology, R, Research, CD117, Therapy, Neurology, Johns Hopkins School of Medicine, Pharmaceutical industry, Upadacitinib, Biochemistry, Jasper

REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper’s Board of Directors. Dr. Brun will also join Jasper’s Research and Development Committee as Chairperson and become a member of Jasper’s Compensation Committee. Concurrently, board member Vishal Kapoor has been appointed to join Jasper’s Audit and Compensation Committees. Additionally, Lawrence Klein, Ph.D., has stepped down from Jasper’s Board of Directors as of June 20, 2023, due to requirements of his recent appointment as a Partner of Versant Ventures.

Key Points: 
  • Dr. Brun will also join Jasper’s Research and Development Committee as Chairperson and become a member of Jasper’s Compensation Committee.
  • Concurrently, board member Vishal Kapoor has been appointed to join Jasper’s Audit and Compensation Committees.
  • Additionally, Lawrence Klein, Ph.D., has stepped down from Jasper’s Board of Directors as of June 20, 2023, due to requirements of his recent appointment as a Partner of Versant Ventures.
  • He was most recently a Senior Advisor to Horizon Therapeutics and Vice President of Scientific Affairs and Head of AbbVie Ventures.

Opthea Appoints Anshul Thakral as Non-Executive Director of the Board

Retrieved on: 
Thursday, June 8, 2023
PPD, Carlyle, Gerson Lehrman Group, University, AMD, ARCH Venture Partners, Biotechnology, Chief commercial officer, GLG, Research, Retina, MBA, Biomedical engineering, McKinsey & Company, Science, Wharton School of the University of Pennsylvania, Johns Hopkins University, Patient, Biomedicine, Widener University Commonwealth Law School, Growth, Pharmaceutical industry, Launch, Thakeham

Concurrently with this appointment, Mr. Michael Sistenich has resigned as a Non-Executive Director, having served for over 7 years on the Board.

Key Points: 
  • Concurrently with this appointment, Mr. Michael Sistenich has resigned as a Non-Executive Director, having served for over 7 years on the Board.
  • Opthea’s Chairman, Dr. Jeremy Levin, commented “We are immensely grateful to Michael for his contribution to Opthea.
  • “I am honored to join the Opthea Board and to work alongside great minds in science and healthcare,” said Mr. Thakral.
  • Mr. Thakral holds a Master’s degree in Biomedical Engineering from Johns Hopkins University and a Masters Business Administration (MBA) from the Wharton School at the University of Pennsylvania.

Reneo Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Thursday, May 4, 2023
Attention, Telephone, BofA Securities, Public access file, Sale, Prospectus, Jefferies Group, Patient, Thakeham, Robert W. Baird, Form, Madison Avenue, Nicollet Mall, Security (finance)

In addition, Reneo has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Key Points: 
  • In addition, Reneo has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
  • In addition to the shares of common stock being sold in the public offering, Reneo also entered into a securities purchase agreement with Abingworth Bioventures 8 LP (Abingworth), pursuant to which Abingworth agreed to purchase Reneo’s shares of common stock at the public offering price, for aggregate gross proceeds of up to approximately $5.0 million, in a concurrent private placement.
  • The sale of these shares of common stock will not be registered under the Securities Act of 1933, as amended.
  • The concurrent private placement is expected to close after the closing of the public offering.

Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, May 3, 2023
Attention, Telephone, BofA Securities, Enterprise file synchronization and sharing, Sale, Prospectus, Jefferies Group, Patient, Thakeham, Robert W. Baird, Form, Madison Avenue, Nicollet Mall, Security (finance)

IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that it has commenced an underwritten public offering of its shares of common stock.

Key Points: 
  • IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that it has commenced an underwritten public offering of its shares of common stock.
  • All of the shares of common stock in the offering are to be sold by Reneo.
  • Reneo also entered into an agreement with Abingworth Bioventures 8 LP (Abingworth), pursuant to which Reneo has agreed to sell its shares of common stock to Abingworth at the public offering price, for aggregate gross proceeds of up to $5.0 million, in a concurrent private placement that is expected to close after the public offering.
  • The sale of these shares of common stock will not be registered under the Securities Act of 1933, as amended.

Soleno Therapeutics Announces Financing Commitment for up to $60 Million

Retrieved on: 
Monday, December 19, 2022
Acceleration, Food, Therapy, Patient, PWS, Degenerative disease, Food and Drug Administration, Ethics, New Drug Application, Security (finance), Pharmaceutical industry, Thakeham

REDWOOD CITY, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a Securities Purchase Agreement with Nantahala Capital Management, LLC, Abingworth LLP and Vivo Capital, LLC for up to $60 million.

Key Points: 
  • “This commitment from top-tier investors is a significant demonstration of confidence ahead of expected data from the randomized withdrawal period of Study C602 in mid-2023.
  • It strengthens our balance sheet both near and longer term and supports continued preparation for our planned New Drug Application submission, as well as the acceleration of commercial readiness activities,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics.
  • “In addition, we are pleased to report that the rate of enrollment in the study at our U.S. sites is progressing in line with our expectations.
  • Patients are randomized to receive either DCCR or placebo for a period of four months.

Aron Ain, Former UKG CEO, to Join Hellman & Friedman as Operating Partner

Retrieved on: 
Thursday, December 8, 2022
Professional Services, Business, Technology, Finance, Software, Banking, Pfizer, Hellman & Friedman, Culture, UKG, PPD, CURIA, Kronos Incorporated, Life, Partnership, Thermo Fisher Scientific, The Carlyle Group, HR, Linsly School, Vernier Software & Technology, Investment, COVID-19, Health, History, Growth, Workforce, Philosophy, Partner, Ultimate Software, Orientation, HCM, Organization, Management, Financial services, Thakeham, Kronos, Cordis

Hellman & Friedman (H&F), a premier global private equity firm, today announced that Aron Ain is joining the firm in an advisory role as an Operating Partner and member of the H&F CEO Council.

Key Points: 
  • Hellman & Friedman (H&F), a premier global private equity firm, today announced that Aron Ain is joining the firm in an advisory role as an Operating Partner and member of the H&F CEO Council.
  • H&F led the take-private transactions for Kronos and Ultimate Software in 2007 and 2019, respectively, which subsequently merged to become UKG in 2020.
  • Aron Ain serves in an advisory role as an Operating Partner with Hellman & Friedman and member of the H&F CEO Council, where he brings more than 40 years of leadership experience.
  • David Simmons serves in an advisory role as an Operating Partner with Hellman & Friedman and member of the H&F CEO Council.